Clinical outcomes of ethnic minority women in MA.17

A trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer

B. Moy, D. Tu, J. L. Pater, J. N. Ingle, L. E. Shepherd, T. J. Whelan, P. E. Goss

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Aromatase inhibitors are widely employed in the adjuvant treatment of early stage breast cancer. The impact of aromatase inhibitors has not been established in ethnic minority women. Patients and methods: The purpose of this study was to evaluate the impact of letrozole on minority women in MA.17, a placebo-controlled trial of letrozole following 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Retrospective comparison of disease-free survival (DFS), side effects, and mean changes in quality of life (QOL) scores from baseline between Caucasian and minority women was performed. Results: Minority (n = 352) and Caucasian (n = 4708) women were analyzed. There was no difference between these groups in DFS (91.6% versus 92.4% respectively for 4 year DFS). Letrozole, compared with placebo, significantly improved DFS for Caucasians (HR = 0.55; P < 0.0001) but not for minorities (HR = 1.39; P = 0.53). Among women who received letrozole, minorities had a significantly lower incidence of hot flashes (49% versus 58%; P = 0.02), fatigue (29% versus 39%; P = 0.005), and arthritis (2% versus 7%; P = 0.006) compared with Caucasians. Mean change in QOL scores for minority women who received letrozole demonstrated improved mental health at the 6-month assessment (P = 0.02) and less bodily pain at the 12-month assessment (P = 0.046). Conclusion: Letrozole improved DFS in Caucasians but a definite benefit in minority women has not yet been demonstrated. Minority women tolerated letrozole better than Caucasians in terms of toxicity. These results need confirmation in other trials of aromatase inhibitors.

Original languageEnglish (US)
Pages (from-to)1637-1643
Number of pages7
JournalAnnals of Oncology
Volume17
Issue number11
DOIs
StatePublished - Nov 2006

Fingerprint

letrozole
Tamoxifen
Breast Neoplasms
Disease-Free Survival
Aromatase Inhibitors
Placebos
Quality of Life
Hot Flashes

Keywords

  • Aromatase inhibitors
  • Early breast cancer
  • Ethnicity
  • Minority race

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clinical outcomes of ethnic minority women in MA.17 : A trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. / Moy, B.; Tu, D.; Pater, J. L.; Ingle, J. N.; Shepherd, L. E.; Whelan, T. J.; Goss, P. E.

In: Annals of Oncology, Vol. 17, No. 11, 11.2006, p. 1637-1643.

Research output: Contribution to journalArticle

Moy, B. ; Tu, D. ; Pater, J. L. ; Ingle, J. N. ; Shepherd, L. E. ; Whelan, T. J. ; Goss, P. E. / Clinical outcomes of ethnic minority women in MA.17 : A trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. In: Annals of Oncology. 2006 ; Vol. 17, No. 11. pp. 1637-1643.
@article{9b0e8a02bcb64d2e81859813fdc1799d,
title = "Clinical outcomes of ethnic minority women in MA.17: A trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer",
abstract = "Background: Aromatase inhibitors are widely employed in the adjuvant treatment of early stage breast cancer. The impact of aromatase inhibitors has not been established in ethnic minority women. Patients and methods: The purpose of this study was to evaluate the impact of letrozole on minority women in MA.17, a placebo-controlled trial of letrozole following 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Retrospective comparison of disease-free survival (DFS), side effects, and mean changes in quality of life (QOL) scores from baseline between Caucasian and minority women was performed. Results: Minority (n = 352) and Caucasian (n = 4708) women were analyzed. There was no difference between these groups in DFS (91.6{\%} versus 92.4{\%} respectively for 4 year DFS). Letrozole, compared with placebo, significantly improved DFS for Caucasians (HR = 0.55; P < 0.0001) but not for minorities (HR = 1.39; P = 0.53). Among women who received letrozole, minorities had a significantly lower incidence of hot flashes (49{\%} versus 58{\%}; P = 0.02), fatigue (29{\%} versus 39{\%}; P = 0.005), and arthritis (2{\%} versus 7{\%}; P = 0.006) compared with Caucasians. Mean change in QOL scores for minority women who received letrozole demonstrated improved mental health at the 6-month assessment (P = 0.02) and less bodily pain at the 12-month assessment (P = 0.046). Conclusion: Letrozole improved DFS in Caucasians but a definite benefit in minority women has not yet been demonstrated. Minority women tolerated letrozole better than Caucasians in terms of toxicity. These results need confirmation in other trials of aromatase inhibitors.",
keywords = "Aromatase inhibitors, Early breast cancer, Ethnicity, Minority race",
author = "B. Moy and D. Tu and Pater, {J. L.} and Ingle, {J. N.} and Shepherd, {L. E.} and Whelan, {T. J.} and Goss, {P. E.}",
year = "2006",
month = "11",
doi = "10.1093/annonc/mdl177",
language = "English (US)",
volume = "17",
pages = "1637--1643",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Clinical outcomes of ethnic minority women in MA.17

T2 - A trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer

AU - Moy, B.

AU - Tu, D.

AU - Pater, J. L.

AU - Ingle, J. N.

AU - Shepherd, L. E.

AU - Whelan, T. J.

AU - Goss, P. E.

PY - 2006/11

Y1 - 2006/11

N2 - Background: Aromatase inhibitors are widely employed in the adjuvant treatment of early stage breast cancer. The impact of aromatase inhibitors has not been established in ethnic minority women. Patients and methods: The purpose of this study was to evaluate the impact of letrozole on minority women in MA.17, a placebo-controlled trial of letrozole following 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Retrospective comparison of disease-free survival (DFS), side effects, and mean changes in quality of life (QOL) scores from baseline between Caucasian and minority women was performed. Results: Minority (n = 352) and Caucasian (n = 4708) women were analyzed. There was no difference between these groups in DFS (91.6% versus 92.4% respectively for 4 year DFS). Letrozole, compared with placebo, significantly improved DFS for Caucasians (HR = 0.55; P < 0.0001) but not for minorities (HR = 1.39; P = 0.53). Among women who received letrozole, minorities had a significantly lower incidence of hot flashes (49% versus 58%; P = 0.02), fatigue (29% versus 39%; P = 0.005), and arthritis (2% versus 7%; P = 0.006) compared with Caucasians. Mean change in QOL scores for minority women who received letrozole demonstrated improved mental health at the 6-month assessment (P = 0.02) and less bodily pain at the 12-month assessment (P = 0.046). Conclusion: Letrozole improved DFS in Caucasians but a definite benefit in minority women has not yet been demonstrated. Minority women tolerated letrozole better than Caucasians in terms of toxicity. These results need confirmation in other trials of aromatase inhibitors.

AB - Background: Aromatase inhibitors are widely employed in the adjuvant treatment of early stage breast cancer. The impact of aromatase inhibitors has not been established in ethnic minority women. Patients and methods: The purpose of this study was to evaluate the impact of letrozole on minority women in MA.17, a placebo-controlled trial of letrozole following 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Retrospective comparison of disease-free survival (DFS), side effects, and mean changes in quality of life (QOL) scores from baseline between Caucasian and minority women was performed. Results: Minority (n = 352) and Caucasian (n = 4708) women were analyzed. There was no difference between these groups in DFS (91.6% versus 92.4% respectively for 4 year DFS). Letrozole, compared with placebo, significantly improved DFS for Caucasians (HR = 0.55; P < 0.0001) but not for minorities (HR = 1.39; P = 0.53). Among women who received letrozole, minorities had a significantly lower incidence of hot flashes (49% versus 58%; P = 0.02), fatigue (29% versus 39%; P = 0.005), and arthritis (2% versus 7%; P = 0.006) compared with Caucasians. Mean change in QOL scores for minority women who received letrozole demonstrated improved mental health at the 6-month assessment (P = 0.02) and less bodily pain at the 12-month assessment (P = 0.046). Conclusion: Letrozole improved DFS in Caucasians but a definite benefit in minority women has not yet been demonstrated. Minority women tolerated letrozole better than Caucasians in terms of toxicity. These results need confirmation in other trials of aromatase inhibitors.

KW - Aromatase inhibitors

KW - Early breast cancer

KW - Ethnicity

KW - Minority race

UR - http://www.scopus.com/inward/record.url?scp=33750585962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750585962&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdl177

DO - 10.1093/annonc/mdl177

M3 - Article

VL - 17

SP - 1637

EP - 1643

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

ER -